AT-301 (Atossa Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

NME

Base Information

Drug NameAT-301 (Atossa Therapeutics)

Drug Alias Nameanti-SARS-CoV-2 spike protein vaccine (Atossa Therapeutics)COVID-19 vaccine (Atossa Therapeutics)SARS-CoV-2 vaccine (Atossa Therapeutics)AT-301BAT-301A

ClassificationSmall molecules

Mechanisms of ActionCoronavirus spike glycoprotein modulatorsProtease inhibitors

TargetsCoronavirus spike glycoproteinProtease

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAtossa Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAtossa Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A